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Abstract Surgical debridement and prolonged systemic
antibiotic therapy are an established management strategy
for infection after tibial fractures. Local antibiotic delivery
via cement beads has shown improved outcome but
requires further surgery for extraction of beads. OSTEO-
SET-T is a resorbable bone void filler composed of cal-
cium sulphate and 4 % tobramycin that is packed easily
into bone defects. This is a review of the outcomes of 21
patients treated with OSTEOSET-T for osteomyelitis of
the tibia. This is a retrospective case note and clinical
review. In all cases, the strategy was debridement, with
removal of any implants, with excision back to bleeding
bone. OSTEOSET-T pellets were packed into any con-
tained defects or the intra-medullary canal with further
bony stabilisation (n = 9) and soft tissue reconstruction
(n = 7) undertaken as required. Intravenous vancomycin
and meropenem were administered after sampling with
substitution to targeted antibiotic therapy for between
6 weeks and 6 months. The average follow-up was
15 months. Union rate after tibial reconstruction was
100 %. Wound complications were encountered in 52 %: a
wound discharge in the early post-operative period was
noted in seven patients (33 %) independent of site of pellet
placement. In the 14 cases without a wound leak, five
developed wound complications (p = 0.06, Fisher’s exact
test) either from delayed wound-healing or pin-site
infections. One patient developed a transient acute kidney
injury and one refractory osteomyelitis. OSTEOSET-T is
an effective adjunct in the treatment of chronic tibial
osteomyelitis following trauma based on the low incidence
of relapse of infection within the period of follow-up in this
study, but significant wound complications and one tran-
sient nephrotoxic event were also recorded.
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Introduction
Antibiotics are an important part of the strategy in treating
infection after tibial fractures. In established osteomyelitis,
surgical debridement is followed with systemic and,
sometimes, local antibiotic delivery. Antibiotic-impreg-
nated cement beads are frequently used as an adjunct to
delivery of antibiotics but often require a further surgical
procedure for removal.
The ability to treat chronic osteomyelitis with single-
stage surgery potentially reduces the risk and morbidity
associated with repeated operative procedures and general
anaesthetic. Reduction in theatre time and length of in-
patient stay are added economic benefits. Despite single-
stage surgery showing reasonable success in achieving union
in infected non-union of long bones, persistent infection and
subsequent revision surgery may be needed [1].
Calcium sulphate has been used successfully in the
treatment of non-union and is an osteo-conductive void
filler that is resorbed at a rate similar to that of bone for-
mation [2, 3]. OSTEOSET-T (Wright Medical Technol-
ogy Inc. Arlington TN USA) comes pre-packaged in small
pellets to allow easy packing into bone. It comes preloaded
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with 4 % tobramycin, and drug elution profiles have shown
levels up to 10,000 times the minimum inhibitory con-
centration for most strains of Staphylococcus [4]. No fur-
ther surgery is required to remove the resorbable pellets.
Animal studies have demonstrated that its use prevents
intramedullary and post-operative wound infection fol-
lowing the treatment of open, contaminated long-bone
fractures [5, 6].
OSTEOSET-T has been used as a bone graft substitute
with success in the management of infected non-union of the
tibia. Management involves radical debridement of infected
bone and placement of gentamicin-impregnated beads, prior
to definitive fixation and the use of OSTEOSET-T [7].
Union was achieved without the need for autologous bone
graft and without recurrence of infection. A retrospective
comparison of the use of OSTEOSET-T with debridement
versus debridement alone has supported the use of OS-
TEOSET-T in single-stage surgery in the treatment of
adult osteomyelitis. Chang et al. [8] have described the use
of vancomycin with OSTEOSET-T for cases of tobramy-
cin resistance. However, it has been associated with wound
complications, e.g. in the development of sinuses draining a
sterile effluent, but this was found to be self-limiting and
resolved after the complete absorption of OSTEOSET-T
and without recurrence of infection [9, 10].
The aminoglycosides used in the treatment of bone
infections belong to the protein synthesis inhibitor family
of antibiotics, binding to the bacterial ribosomal 30S sub-
unit to achieve a bacteriostatic effect through transcription
errors during cell division [11]. An additional ability to
disrupt bacterial cell membranes accounts for its bacteri-
cidal properties [12]. They have a broad spectrum and are
effective against both gram-positive and gram-negative
organisms [13]. Pseudomonas aeruginosa, Staphylococcus
aureus and Enterobacteriaceae are sensitive to tobramycin
which has a lower side-effect profile than gentamicin [14].
This case series reports on the outcome of 21 patients
with chronic osteomyelitis managed by single-stage sur-
gery and using OSTEOSET-T as an adjunct to intrave-
nous antimicrobial therapy.
Materials and Methods
Twenty-one cases of chronic tibial osteomyelitis in which
treatment involved the use of OSTEOSET-T as a space
filler and local antibiotic delivery system were identified by
a retrospective review over a 30-month period from 2010 to
2012. Data were collected using a proforma and included
demographics, record of the intra-operative procedure, rel-
evant microbiology, renal function, complications relating
to recurrent infection and wound healing, the presence of a
wound leak and repeat surgeries. A wound leak was defined
subjectively as a serous leakage considered a potential risk
to normal wound healing [15]. A standardised surgical
protocol and antibiotic regime based on guidance from our
local microbiology department were followed.
In all cases, surgery was directed at excising infected
tissue and sinuses; a radical debridement was performed,
guided by pre-operative magnetic resonance imaging, until
bleeding confirmed on residual bone. Metalwork, if present,
was removed. Once complete, OSTEOSET-T pellets were
packed into any defects or into the intra-medullary canal in
those cases where an intramedullary nail had been removed.
Further, tibial stabilisation and soft tissue cover were carried
out as deemed necessary. The protocol involved taking a
minimum of five tissue samples from deep tissues using
fresh instruments for each sample. Empiric intravenous
vancomycin and meropenem were administered after sam-
ples were taken. Meropenem was discontinued after 3 days
in the absence of gram-negative growth, and vancomycin
continued until the 7-day culture results became available.
Thereafter, targeted antibiotic therapy was continued for a
period of 6 weeks to 6 months, or empiric ciprofloxacin and
rifampicin if no growth was seen. This approach is based on
the probability of involvement of a Staphylococcus bacte-
rium species contraposed to local antibiotic resistance pat-
terns and the previous published literature on the
effectiveness of combination of dual therapy [15–17].
Data analysis and parametric tests were performed using
Microsoft Excel for Mac 2011, while nonparametric sta-
tistical tests done with GraphPad QuickCalcs (2013
GraphPad Software, Inc.). Statistical significance was set at
p value of B0.05.
Results
There were 18 males and 3 females with a mean age of 49
(range 26–88) and follow-up of 16 months (range 6–25).
Six patients were classified as Cierney-Mader grade 3A,
one patient as grade 3B, 13 patients grade 4A, and one
patient grade 4B. In situ metal work was removed (Fig. 1).
Fig. 1 Cases of non-union and the presence of metal work
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Nine cases required fixation: eight with circular external
fixators and one with a monolateral external fixator. Seven
cases required reconstructive soft tissue cover provided by
our resident plastic surgical team: there were four local
flaps and three free vascularised flaps.
Microbiological analysis of the samples revealed 38 %
of the infections were caused by a strain of Staphylococcus
species. A significant number either had mixed growth or
no identified growth. This is summarised in Table 1. Renal
function was assessed in all cases. One case was compli-
cated by a transient post-operative acute kidney injury
which resolved after 1 week without the need for renal
support. This patient had pre-existing comorbidities of
obesity and essential hypertension.
Seven cases were complicated by wound leakage; the
location of OSTEOSET-T pellets in either a closed
intramedullary cavity or an open cortical defect did not
relate to its incidence (Fig. 2). Three-quarters of these
cases with a wound leak went on to have problems with
wound healing as compared to just one-third of the cases
without a leak. A serous leak appears to double the relative
risk of wound-healing problems (Fig. 3).
Successful eradication of infection, as determined in the
time of follow-up in this series, was achieved in 20 cases.
Only one patient required further debridement and soft
tissue coverage and remained free of continuing infection
at latest follow-up. One patient required further surgery for
the correction of residual deformity.
Figures 4, 5, 6, 7 and 8 show the successful management
of a 57 year old man with post traumatic chronic tibial
osteomyelitis using OSTEOSET-T as an adjunct to sur-
gical debridement.
Discussion
This case series included a sample of patients with chronic
osteomyelitis of the tibia secondary to trauma. The use of
OSTEOSET-T was an effective adjunct with eradication of
infection in all of our cases in the period of follow-up,
although one patient required a further surgical debridement
owing to an unhealthy appearance of the wound and suspected
Table 1 Causative organisms involved
Organism Cases %
Polymicrobial 4 19
Coagulase-negative Staphylococci 4 19
Staphylococcus aureus 4 19
Negative cultures 3 14






Fig. 2 Impact of site of placement of OSTEOSET-T placement and
the presence of a post-operative wound leak (p = 1.0, Fisher’s exact
test)
Fig. 3 Impact of wound leakage on healing (p = 0.06, Fisher’s exact
test)
Fig. 4 Pre-operative plain radiograph of the right distal tibal in a 57
year old male with chronic post-traumatic osteomyelitis distal tibia
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persistent infection. The occurrence of a sterile effluent was a
significant complication, as was its associated risk of impaired
wound healing. Reported concerns over acute kidney injury
(potential nephrotoxic side-effect of high local concentrations
of aminoglycosides) were unfounded in our series; the one
incident of transient acute kidney injury seen was thought to
have occurred from the intravenous antimicrobial therapy in a
patient with a background of hypertensive nephropathy.
This case series is limited by the following: the absence
of a control group, small numbers and the minimum follow-
up period of 6 months. A retrospective case–control study,
which contained a mixed group of long-bone infections,
found favour in the use of OSTEOSET-T [8]. Prospective
Fig. 5 MRI appearances of chronic osteomyelitis of the right distal
tibia
Fig. 6 Intra-operative use of OSTEOSET-T
Fig. 7 Post-operative plain radiograph of right distal tibia packed
with OSTEOSET-T
Fig. 8 Plain radiograph of the right distal tibia following second
stage bone grafting
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data on OSTEOSET-T are limited, with published work
concentrating on post-traumatic osteomyelitis in long bones
but without comparison with controls [9].
Conclusion
This case series supports continued use of OSTEOSET-T
as an adjunct in the treatment of chronic osteomyelitis of
the tibia following trauma but highlights potential issues
with wound problems. Further prospective and controlled
studies are needed to evaluate the role of local antibiotic
delivery systems in the treatment of chronic osteomyelitis.
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